MedTrace Logo

FORTRAS: A Study of MSK-TCR5 in People With Solid Tumor Cancers

NCT07638371 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2026-06-15

No results posted yet for this study

Summary

The purpose of this study is to test the safety of MSK-TCR5 in participants with advance solid tumor cancer that has a KRAS, HRAS, or NRAS G12D mutation.

Conditions

  • Solid Tumor
  • Solid Carcinoma
  • Advanced Solid Tumor
  • Unresectable Solid Tumor
  • Metastatic Solid Tumor

Interventions

BIOLOGICAL

MSK-TCR5

MSK-TCR5, created in participant-derived T cells and autologously reinfused into eligible participants following lymphodepleting chemotherapy

Sponsors & Collaborators

Principal Investigators

  • Adam Schoenfeld, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-09
Primary Completion
2030-06-09
Completion
2030-06-09

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07638371 on ClinicalTrials.gov